Becton, Dickinson and Company $BDX Shares Sold by Truist Financial Corp

Key Points

• Truist Financial Corp reduced its stake in Becton, Dickinson and Company by 14.7% during the 2nd quarter, now owning approximately 0.06% of the company valued at $30.31 million.
• Becton, Dickinson and Company's quarterly earnings beat analysts' expectations with an EPS of $3.68, compared to estimates of $3.40, and reported a 10.4% year-over-year revenue increase.
• The company declared a quarterly dividend of $1.04, representing an annualized dividend yield of 2.2%, with a payout ratio currently at 74.82%.

Truist Financial Corp lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 14.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 175,964 shares of the medical instruments supplier's stock after selling 30,370 shares during the quarter. Truist Financial Corp owned about 0.06% of Becton, Dickinson and Company worth $30,310,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $27,000. Alpine Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $31,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Up 0.3%

Shares of Becton, Dickinson and Company stock opened at $191.43 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The business's fifty day moving average price is $188.87 and its two-hundred day moving average price is $187.95. The company has a market capitalization of $54.87 billion, a P/E ratio of 34.43, a PEG ratio of 1.49 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock valued at $562,036 over the last quarter. Insiders own 0.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on BDX shares. Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 target price on the stock. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Argus boosted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Morgan Stanley raised their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.